Blood stream infection (BSI) and acute GVHD (aGVHD) are serious complications of hematopoietic SCT (HSCT). We hypothesized that the two events were not independent of one another. We studied (1) associations between BSI and aGVHD; and (2) the impact of BSI and/or aGVHD on death within 100 days after HSCT, using a retrospective cohort analysis. Risk factor analysis was carried out using multivariable Cox proportional hazards analyses. Of 211 patients who underwent allogeneic HSCT from January 2000 to December 2005 (58% of whom underwent reduced intensity transplantation), 82 (39%) developed BSI. In 49 patients (23%), grade (gr) 2-4 aGVHD occurred. Early BSI was independently associated with an increased occurrence of subsequent aGVHD gr 2-4. CMV seropositivity was independently associated with decreased occurrence of aGVHD. aGVHD gr 2-4 independently predicted subsequent first BSI. Both BSI and aGVHD gr 2-4 were significant independent predictors of death within 100 days after HSCT. There is a strong, independent association between BSI and aGVHD. Potential explanations include the elaboration of cytokines during BSI favoring the development of aGVHD and/or the immunosuppressive treatment of aGVHD favoring the development of BSI. Future studies should be directed at the mechanistic investigations of this association.
Introduction
Blood stream infection (BSI), the most common infectious complication of hematopoietic SCT (HSCT), and acute GVHD (aGVHD) are independent predictors of mortality after HSCT. 1 The conditions favoring the development of aGVHD are thought to occur in the earliest phases of SCT. [2] [3] [4] Intense chemotherapy and irradiation result in damage to the gastrointestinal tract, allowing bacterial constituents to enter the systemic circulation. This results in stimulation of the host immune response, manifested, in part, by the production of inflammatory cytokines. Consequently, graft T cells are pushed along the Th-1 pathway and adopt an alloreactive phenotype, resulting in an immune response against the host. We felt that this sequence of events in the development of aGVHD parallels the immunological events that occur in infection.
Our primary hypothesis was that early BSI promotes the development of aGVHD. A secondary hypothesis was that aGVHD promotes the development of BSI, as a consequence of the immunosuppression used to treat GVHD, and skin and mucosal changes. We studied (1) the temporal relationship between BSI and aGVHD to determine whether time-dependent relationships existed, and (2) the association of these complications of HSCT with all-cause mortality.
Materials and methods

Patient population
We retrospectively studied consecutive allogeneic HSCT recipients who were cared for at Tufts Medical Center from 1 January 2000 to 31 December 2005. Most patients undergoing full-dose HSCT received a conditioning regimen of CY usually with TBI. T-cell depletion was rarely carried out. Patients undergoing reduced intensity HSCT underwent extracorporeal photopheresis and reduced-dose TBI, and were administered pentostatin. 5 All patients were cared for in the same unit by nurses specializing in HSCT, except for the extremely rare circumstance when they required intensive care. Supportive care for all patients was identical and consisted of the following. Patients received antimicrobial prophylaxis with fluoroquinolone, fluconazole and acyclovir, all continuing until engraftment. After engraftment, patients received prophylaxis for Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole until 1 year after HSCT. IVIG was administered to patients who underwent allogeneic HSCT, for the first 7 months after HSCT. Initial aGVHD prophylaxis in recipients of allogeneic HSCT consisted of CYA and MTX, followed by CYA alone. CYA was tapered off and replaced by mycophenolate mofetil, which was continued for 1 year after HSCT unless GVHD developed. Central venous catheters were present in all patients who underwent HSCT, and were generally removed after engraftment. Routine catheter care for all patients was identical and conformed to the Tufts Medical Center Infection Control standards. This study was approved by the Tufts Medical Center Institutional Review Board.
Definitions
The definition of BSI was adapted from the 2004 Center for Disease Control and Prevention's definitions for nosocomial infections. 6 BSI was defined as the isolation of bacteria that are not normally known to colonize the skin, such as Gram negative bacilli, or certain pathogens such as Staphylococcus aureus or fungi, from at least one blood culture. 7 For bacteria that typically colonize the skin, such as coagulase-negative Staphylococcus, Propionibacterium, viridans group of Streptococcus and non-JK strains of Corynebacterium, two consecutive positive blood cultures, two positive blood cultures within 72 h, or one positive blood culture and one positive intravascular catheter tip culture within 72 h constituted a BSI. All blood cultures were obtained in response to an indication of infection, usually fever (oral temperature X38 1C). The criterion for engraftment was an ANC of 500/mm 3 or greater for three consecutive days. Acute GVHD was graded according to the standard criteria. 8 Mucositis was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0. 9 
Data collection
Prespecified demographic and clinical variables were abstracted from the HSCT database and the medical record. The time period of interest was from 7 days before stem cell infusion, which marked the initiation of the conditioning regimen, until 100 days after the infusion. Variables included those fixed before the initiation of the transplantation process: age, gender, previous transplantation, the indication for HSCT, disease status at transplantation, type of HSCT, degree of HLA matching and CMV serologies of the recipient and the donor. Additional variables were potential events occurring at the start of the conditioning regimen through the end of the observation period. These included time to first BSI, time to early BSI, defined as occurring within 7 days before and until 10 days after HSCT, time to engraftment, time to development of the first GVHD gr 2 or higher event and time to death. We chose to study aGVHD gr 2 or higher events, as these gr's are associated with increased morbidity and mortality and require immunosuppressive treatment.
10,11
Statistics Cox proportional hazards regression reporting hazard ratios (HRs) and 95% confidence intervals (CIs) were used in univariate analyses and the multivariable analysis for time to death within 100 days after HSCT. Outcomes of interest were time to first aGVHD gr 2 or higher events, time to first BSI and time to death. Variables analyzed included demographic factors (age, gender), underlying disease necessitating HSCT, number of chemotherapy cycles and classes of agents administered within the 6 months before HSCT, and type of HSCT. In addition, the following variables were expressed as time-dependent variables to examine their temporal relationship: time to engraftment, time to first BSI and time to development of the first aGVHD gr 2 or higher event. Observations were censored at death or day 100 if the patient survived without the outcome of interest. In addition, for certain analyses, patients were censored at day 42 after HSCT if they did not engraft by then. The assumption of proportional hazards was checked using Schoenfeld residuals, Pearson's correlation coefficient, and the %schoen and %daspline macros in SAS. 12, 13 For multivariable analyses, variables using parameter estimates with a P-valuep0.10 in the univariate analyses were included. Multivariable analyses of the outcomes of time to aGVHD or BSI were performed with competing risks models that utilized cause-specific HRs (CSHRs). 14, 15 The competing risk was all-cause mortality. Differences between the groups in Kaplan-Meier analyses were determined by the log-rank test. In all analyses, a P-value of p0.05 was considered statistically significant.
Results
Patient population
Two hundred and eighteen patients underwent consecutive allogeneic HSCT during the study period. Of these, 211 had data on the outcomes of aGVHD, BSI and death. Their characteristics are showed in Table 1 . Data on mucositis were complete for 207 patients. Data on chemotherapy within the 6 months before HSCT were complete in 199-204 patients, depending upon the class of agent (Table 2) .
Acute GVHD Forty-nine patients (23%) developed an aGVHD gr 2 or higher event. Thirty-four of these had aGVHD gr 1, which then progressed to a more severe stage. There were 89 patients (42%) who developed aGVHD gr 1 only, and 73 patients (35%) who had no aGVHD episodes. The median time to development of aGVHD gr 1 was 16 days (interquartile range (IQR 25th and 75th percentiles, IQR) 12, 19 days) and to an aGVHD gr 2 or higher event was 24 days (IQR 16, 36 days). Our preliminary analyses revealed that there was no relationship between the occurrence of BSI and subsequent aGVHD gr 1 (data not shown). Because of this and the clinical significance of more severe grades of aGVHD, we limited our remaining analyses to aGVHD gr 2 or higher events, unless otherwise mentioned.
Univariate analysis of time to aGVHD gr 2 or higher events BSI occurring before aGVHD was the primary predictor of interest. Thus, BSI that occurred after an aGVHD gr 2 or higher event was censored, and only BSI that occurred before an aGVHD gr 2 or higher event was assessed. In the univariate analysis, previous HSCT, CMV seropositivity of the recipient and receipt of etoposide within the 6 months before HSCT were predictive or trended toward being predictive of a reduced risk of developing an aGVHD gr 2 or higher event. BSI that occurred at any time between the initiation of the conditioning regimen 7 days before stem cell infusion and development of an aGVHD gr 2 or higher event, the censoring event of death or day 100, whichever came first, was not predictive of an increased risk of developing an aGVHD gr 2 or higher event. However, early BSI occurring between the initiation of the conditioning regimen and 10 days after stem cell infusion (n ¼ 28)
predicted an increased risk of developing an aGVHD gr 2 or higher event. All cases of early BSI occurred before any aGVHD or censoring events. We graphically examined the relationship between early BSI and development of an aGVHD gr 2 or higher event using Kaplan-Meier analysis ( Figure 1 ). Again, it appeared that patients with early BSI were more likely to develop an aGVHD gr 2 or higher event (P ¼ 0.05). Age, gender, HLA match between the donor and the recipient, underlying disease (categories collapsed to lymphoma, leukemia and other causes for the sake of analysis), reduced-intensity HSCT, disease status at HSCT, donor CMV serology and time to engraftment did not predict the risk of developing a subsequent aGVHD gr 2 or higher event. In addition, mucositis gr's 3-4 within 14 days of HSCT, occurring in 21 patients (44%) with and 64 patients (41%) without an aGVHD gr 2 or higher event, was not associated with aGVHD when compared with mucositis gr's 0-2. There was a trend toward reduced risk of developing aGVHD gr 2 or higher events in patients who received etoposide (HR 0.35, 95% CI 0.11, 1.11, P ¼ 0.08). When adjusting for underlying disease, this relationship did not change. There was no relationship between aGVHD and the number of cycles of chemotherapy or classes of agents used within the 6 months before HSCT.
Multivariable analysis of time to an aGVHD gr 2 or higher event We utilized cause-specific HRs (CSHRs) to assess the risk factors for developing an aGVHD gr 2 or higher event, (22) 7 (14) Abbreviations along with the competing risk of all-cause mortality within 100 days of HSCT. Variables analyzed in this model were early BSI, previous HSCT, CMV seropositivity of the recipient and receipt of etoposide within the 6 months before HSCT (Table 3 ). The analysis revealed that those persons experiencing an early BSI had a more than twofold increased risk of developing a subsequent aGVHD gr 2 or higher event (CSHR 2.17, 95% CI 1.05, 4.49, P ¼ 0.04). CMV seropositivity of the recipient remained a significant predictor of reduced risk of developing an aGVHD gr 2 or higher event whereas previous HSCT and receipt of etoposide within the 6 months before HSCT were not statistically significant predictors. As engraftment was a predictor of BSI (see below), to avoid confounding we repeated the analysis, by censoring the three patients who did not engraft by day 42. The results of the analysis were not substantially different. Early BSI was still an independent risk factor for developing a subsequent aGVHD gr 2 or higher event.
It is possible that aGVHD gr 1 increased the risk for subsequent early BSI, and independently led to progression to more severe grades of aGVHD, without any influence of early BSI on the development of an aGVHD gr 2 or higher event. However, in each patient with early BSI, any aGVHD gr 1 event occurred after early BSI. Therefore, it would be unlikely that aGVHD gr 1 increased the risk of early BSI. In addition, it was apparent that early BSI did not predict an increased risk of developing a subsequent aGVHD gr 1 (univariate analysis, HR ¼ 1.05, 95% CI 0.61, 1.80, P ¼ 0.86). Therefore, there did not appear to be a confounding relationship between early BSI and aGVHD gr 1.
Blood stream infection
Eighty-two patients (39%) developed BSI during the study period at a median of 20 days (IQR 6, 46 days) after stem cell infusion. Twenty-eight patients (13%) developed early BSI at a median of 4 days (IQR 1, 7 days) after stem cell infusion. There were 96 blood isolates obtained from the first BSI episodes of the 82 individuals. Gram-positive cocci were the most common type of isolate. Of these, 79 (or 49% of the total number of isolates) were coagulase-negative Staphylococci.
Univariate analysis of the time to first BSI We examined the outcome of time to first BSI, wherein the predictor variable of interest was a first aGVHD gr 2 or higher event. aGVHD gr 2 or higher events that occurred after BSI were censored. In the univariate analysis, an aGVHD gr 2 or higher event predicted a twofold increase in the likelihood of a subsequent BSI. In addition, a 6/6 HLA locus match between the donor and the recipient, and engraftment as a categorical variable predicted a decrease in the likelihood of BSI. Underlying disease (that was collapsed to lymphoma, leukemia or other causes for the sake of analysis) and time to engraftment were not predictive of BSI. In addition, mucositis grades 3-4, occurring in 31 patients (40%) with and 54 patients (42%) without BSI, was not associated with BSI when compared with mucositis grades 0-2.
Agents used to treat hematological diseases can have an effect on the resident bacteria. [16] [17] [18] Therefore, we sought to determine whether the number of chemotherapy cycles or specific classes of chemotherapeutic agents used within the 6 months before HSCT were associated with BSI. Of the patients who developed BSI, 17 (22%), 33 (42%), 22 (29%) Table 3 Multivariable analysis of cause-specific hazard ratios for the development of acute GVHD grade 2 or higher events and 7 (9%) patients received 0, 1-2, 3-4 and at least 5 cycles, respectively, of chemotherapy 6 months before HSCT, compared with 29 (23%), 60 (47%), 27 (21%) and 11 (9%) of patients who did not develop BSI, who received 0, 1-2, 3-4 and at least 5 cycles, respectively, of chemotherapy 6 months before HSCT. Similarly, in those who did and did not develop BSI, there were no differences between the proportions of patients who received the following classes of agents: alkylating agents, antimetabolites, anthracyclines, vinca alkaloids, etoposide or antibodies active against leukocytes (data not shown).
Multivariable analysis of time to first BSI A competing risks model incorporating all-cause mortality was constructed, using CSHRs. Variables incorporated into this model were degree of HLA matching, engraftment as a categorical variable, aGVHD gr 2 or higher event and previous HSCT. In this model, an aGVHD gr 2 or higher event predicted an increased risk of subsequent BSI, whereas HLA matching was associated with a reduction in the risk of BSI (Table 4) . Previous HSCT and engraftment were not independent predictors of BSI.
Mortality
Forty-nine patients (23%) died by the end of the observation period of 100 days. The median time to death of those patients was 53 days (IQR 28, 78 days). We examined the factors that were associated with death, including BSI and an aGVHD gr 2 or higher event.
Univariate analysis of time to death BSI, expressed as either a categorical or a time-dependent variable, was associated with an increased risk of death within 100 days after HSCT. An aGVHD gr 2 or higher event when expressed as a time-dependent variable, previous HSCT, receipt of etoposide within the 6 months before HSCT and of an alkylating agent during that time frame were also associated with an increased risk of death. When adjusted for underlying disease, receipt of these chemotherapeutic classes was still predictive of mortality. Engraftment, expressed as a categorical variable, and a 6/6 HLA match between the donor and the recipient were associated with a decreased risk of death. Age, gender, underlying disease, type of HSCT (reduced-intensity vs full-dose HSCT), mucositis gr's 3-4, time to engraftment and early BSI were not associated with an increased or decreased risk of death (data not shown).
Multivariable analysis of time to death
In the first multivariable analysis, the following variables were incorporated: BSI, an aGVHD gr 2 or higher event, HLA match, engraftment as a categorical variable and previous HSCT. BSI, an aGVHD gr 2 or higher event and previous HSCT were independently associated with death within 100 days after HSCT (Table 5 ). In the multivariable model, engraftment was highly associated with survival, whereas there was a trend toward an association between the degree of HLA matching and survival. We performed subsequent analyses identical to the one described above except, that receipt of etoposide or receipt of an alkylating agent within the 6 months before HSCT was substituted for HLA matching. Receipt of either agent was associated with an increased risk of death (etoposide: n ¼ 199, HR 2.65, 95% CI 1.37, 5.13, P ¼ 0.004; alkylating agent: n ¼ 200, HR 2.04, 95% CI 1.10, 3.76, P ¼ 0.02).
Discussion
We found that early BSI occurring between the start of the conditioning regimen and 10 days after HSCT was independently associated with a twofold increase in the risk of developing a subsequent aGVHD gr 2 or higher event. CMV serology of the recipient but not of the donor was also independently associated with the risk of developing an aGVHD gr 2 or higher event in that a positive serology was predictive of a substantial decrease in the risk. We also determined that the development of an Table 4 Multivariable analysis of cause-specific hazard ratios for the acquisition of blood stream infection aGVHD gr 2 or higher event was associated with an increased risk of subsequent first BSI. Engraftment was not associated with BSI. Finally, both BSI and an aGVHD gr 2 or higher event were independently associated with mortality. Bacterial components, specifically lipopolysaccharide from gastrointestinal microorganisms, leak from the gastrointestinal tract after tissue damage induced by the conditioning regimen and enter the systemic circulation, where, the bacterial components contribute to the activation of donor T cells via APCs, favoring the development of aGVHD. 3 As supporting evidence, patients with higher degrees of gastrointestinal injury and mucosal permeability during the HSCT process had an increased likelihood of developing aGVHD. 19 We reasoned that there would be similar consequences for aGVHD in the course of an active blood stream infection. To our knowledge, this is the first demonstration of an association between BSI and subsequent aGVHD. In our study, only early BSI was associated with an increased risk of aGVHD. Acute GVHD appeared at a median of 16 days after stem cell infusion, implying that the critical events that promote aGVHD occur within days to weeks after stem cell infusion, consistent with the timing of early BSI.
The relationship between CMV and aGVHD is complex, as is reflected by a lack of consensus in the literature. Contributing to the complexity are differences in study populations with regard to stem cell source, donor/recipient matching status, and immunosuppressive and conditioning regimens. In addition, the studies differ in the approaches to CMV assessment, such as by donor and/or recipient serostatus, CMV antigenemia, CMV viremia, the presence of CMV in tissue specimens and CMV disease.
Several studies have focused on whether or not CMV increases the likelihood of aGVHD. Recipient CMV seropositivity was associated with an increased likelihood of aGVHD in some but not all studies. [20] [21] [22] [23] Similar disagreement has been found with regard to the association of donor CMV serostatus with aGVHD. 24, 25 CMV reactivation as detected by CMV DNA in peripheral blood leukocytes, positive blood culture or positive tissue biopsy was not associated with an increased risk of developing a subsequent aGVHD. [26] [27] [28] Several investigators have shown an increased risk of CMV reactivation or disease after the onset of aGVHD, although this finding was not universal. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] However, to our knowledge, no study has shown an association between recipient CMV seropositivity and a reduction in aGVHD as we have in the current study.
There are potential biological mechanisms to explain the association between recipient CMV seropositivity and a reduction in subsequent aGVHD. For example, CMV infection, but not latency, induces immunomodulatory changes, including a decrease in the expression of major histocompatibility Ags and inhibition of NK cell activation (reviewed in Mocarski 38, 39 and Peggs and Mackinnon
40
). In addition, the CMV genome encodes for a protein that is a homolog of IL-10, a human cytokine thought to diminish the aGVHD response through its anti-inflammatory activity. In summary, it could be postulated that silent reactivation of CMV in the early post-HSCT time period could result in a dampening of the immune response at a time when the donor cells are most susceptible to either pro-or antiinflammatory influences, resulting in a decrease in the risk of aGVHD.
CMV reactivation can occur early, even within 1 week of stem cell infusion, although most patients reactivate later in their course 27, [29] [30] [31] [32] 35 ). In these studies, the predominant methods of determining reactivation were by Ag detection, culture or PCR of the blood. It is possible that the blood compartment is not the most relevant site to detect CMV reactivation associated with the immunomodulation of donor cells. In addition, in some studies, CMV reactivation was not sought until after engraftment, after aGVHD developed or until at least 1 week after stem cell infusion. Therefore, little detailed information is available regarding CMV reactivation in the blood or other compartments in the days before and just after stem cell infusion.
It seems intuitive that aGVHD is associated with an increased risk for bacterial infection, either because of immunosuppressive medications used in its treatment 41 or because of providing portals of entry through the skin and/or gastrointestinal tract. However, there are conflicting data. Several studies have shown an increased risk of bacterial infection, particularly BSI, after the onset of aGVHD, as was shown in the present study, whereas others have not. 30, [41] [42] [43] [44] The possible reasons for different findings among studies include differences in analytical approaches, such as assessing aGVHD as a time-dependent variable, and heterogeneity in types of HSCT, such as reducedintensity HSCT, use of T-cell depletion, and the proportion of related vs unrelated donors.
There are several limitations to this study. For example, the association between early BSI and development of a subsequent aGVHD gr 2 or higher event is at the borderline of statistical significance. This might be related to the small number of early BSI cases or to a weak relationship between the two events. In addition, as this was a retrospective study, certain variables, such as the occurrence of CMV reactivation and disease, were not available.
The association between BSI or aGVHD and mortality after HSCT has been observed by us and others. 1, 11, [45] [46] [47] In addition, BSI and/or aGVHD are associated with longer lengths of stay, re-admission to the hospital, fungal infection resulting in death, and increased costs of care.
1,47-50 Therefore, it is important to further study the interrelationships between these two common and serious complications in the hope of improving the outcomes of HSCT.
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